Literature DB >> 1531155

Cortical glucose metabolism in Huntington's disease.

W R Martin1, C Clark, W Ammann, A J Stoessl, W Shtybel, M R Hayden.   

Abstract

We measured cortical glucose metabolism with positron emission tomography in 39 patients with Huntington's disease (HD) and in 34 controls. In the 23 patients with symptoms for less than 5 years, there was a 15% decrease in metabolism in frontal and inferior parietal cortex. In 16 patients with symptoms for more than 5 years, all cortical areas (except temporal) were significantly involved, with metabolic rates 25 to 30% below those of controls. These data indicate the presence of a diffuse abnormality of cortical function with early involvement of frontal lobes in HD, suggesting that the clinical manifestations may not be related solely to basal ganglia pathology, even in early disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1531155     DOI: 10.1212/wnl.42.1.223

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  23 in total

Review 1.  Aspects of PET imaging relevant to the assessment of striatal transplantation in Huntington's disease.

Authors:  L Besret; A L Kendall; S B Dunnett
Journal:  J Anat       Date:  2000-05       Impact factor: 2.610

Review 2.  Applications of positron emission tomography (PET) in neurology.

Authors:  Y F Tai; P Piccini
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

Review 3.  PET/CT in diagnosis of movement disorders.

Authors:  Valentina Berti; Alberto Pupi; Lisa Mosconi
Journal:  Ann N Y Acad Sci       Date:  2011-06       Impact factor: 5.691

4.  Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: a proton magnetic resonance spectroscopy study.

Authors:  L Harms; H Meierkord; G Timm; L Pfeiffer; A C Ludolph
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-01       Impact factor: 10.154

Review 5.  Mitochondrial matters of the brain: the role in Huntington's disease.

Authors:  C Turner; A H V Schapira
Journal:  J Bioenerg Biomembr       Date:  2010-06       Impact factor: 2.945

6.  Benzodiazepine receptor quantification in Huntington's disease with [(123)I]omazenil and SPECT.

Authors:  L H Pinborg; C Videbaek; S G Hasselbalch; S A Sørensen; A Wagner; O B Paulson; G M Knudsen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154

7.  Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease.

Authors:  S Palfi; R J Ferrante; E Brouillet; M F Beal; R Dolan; M C Guyot; M Peschanski; P Hantraye
Journal:  J Neurosci       Date:  1996-05-01       Impact factor: 6.167

8.  Neocortical neurotransmitter markers in Huntington's disease.

Authors:  S J Pearson; G P Reynolds
Journal:  J Neural Transm Gen Sect       Date:  1994

Review 9.  Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease.

Authors:  Rodrigo A Quintanilla; Gail V W Johnson
Journal:  Brain Res Bull       Date:  2009-07-19       Impact factor: 4.077

Review 10.  Therapeutic approaches to preventing cell death in Huntington disease.

Authors:  Anna Kaplan; Brent R Stockwell
Journal:  Prog Neurobiol       Date:  2012-08-28       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.